Medarex Inc.

E. R. Squibb Sons, Inc.

Amgen Inc.

Bristol-myers Squibb Compnay

Alison Witte

Josephine M Cardarelli

Haichun Huang

Mohan Srinivasan

David J King

David B Passmore

Francis Hall Martin

Denise Leah Williams

Brian C Varnum

Xueming Qian

Chris Vezina

Gary Elliott

Paul O Sheppard

Scott R Presnell

Alan J Korman

Mark J Selby

Mark W Rixon

Guodong Chen

Stanley Richard Krystek, Jr

Peter Brams

Indrani Chakraborty

Eric H Holmes

Brenda L Stevens

Li-Sheng Lu

Susan Wong

Thomas D Kempe

Hui Wei

Lumelle A Schneeweis

Cynthia A Vistica

Heidi N Leblanc

Kristopher Toy

Mark Yamanaka

Richard Theolis

Chetana Rao-Naik

Dawn M Tanamachi

Kyra D Zens

Frank Martin

Steven Sheriff

Tim Sproul

Asna Masood

Sarah R Reed

Gary Elliot

Josphine M Cardelli

Nels B Hamacher

Susan C Wong

Stanley R Krystek

Mian Gao

Tracy Arakaki

Kateri Atkins

Thomas Edwards

Noah Ditto

Sara R Dwiggins

David John King

David King

The present invention provides isolated human monoclonal antibodies that bind to IFNAR-1 and that are capable of inhibiting the biological activity of Type I interferons. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting Type I interferon-mediated disorders using the antibodies of the invention, including methods for treating autoimmune disorders, transplant rejection or Graft Versus Host Disease using the antibodies of the invention.

Interferon receptor 1 antibodies and their uses

The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.

Methods of treating inflammation with IL-17A/F and IL-23P19 bispecific antibodies

The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to O8E with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for treating cancer.

Human monoclonal antibodies to O8E

Polynucleotides encoding IL-17/IL-23 bispecific, IL-17A/F and IL-23p19 antibodies

The present invention provides isolated anti-interferon alpha monoclonal antibodies, particularly human monoclonal antibodies, that inhibit the biological activity of multiple interferon (IFN) alpha subtypes but do not substantially inhibit the biological activity of IFN alpha 21 or the biological activity of either IFN beta or IFN omega. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the biological activity of IFN alpha using the antibodies of the invention, as well as methods of treating disease or disorders mediated by IFN alpha, such as autoimmune diseases, transplant rejection and graft versus host disease, by administering the antibodies of the invention.

Methods for preparing interferon alpha antibodies

The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to Fucosyl-GM1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting Fucosyl-GM1, as well as methods for treating various diseases, including cancer, using anti-Fucosyl-GM1 antibodies.

Human monoclonal antibodies to fucosyl-GM1 and methods for using anti-fucosyl-GM1 antibodies

Antibodies that interact with interleukin-1 receptor type 1 (IL-1R1) are described. Methods of treating IL-1 mediated diseases by administering a pharmaceutically effective amount of antibodies to IL-1R1 are described. Methods of detecting the amount of IL-1R1 in a sample using antibodies to IL-1R1 are described.

Therapeutic human anti-IL-1R1 monoclonal antibody

The present disclosure provides isolated monoclonal antibodies that specifically bind to CD22 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD22, as well as methods for treating various cancers and inflammatory and autoimmune disorders using an anti-CD22 antibody of this disclosure.

Human antibodies that bind CD22 and uses thereof

Human monoclonal antibodies to Fucosyl-GM1 and methods for using anti-Fucosyl-GM1 antibodies

Bispecific antibodies to IL-23 and IL-17A/F

Nucleic acids encoding interferon alpha antibodies

Growing community of inventors

Scotts Valley, CA, United States of America

Alison Witte